NASDAQ:BIOC - Biocept Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.8173 +0.05 (+6.52 %) (As of 12/16/2018 04:00 PM ET)Previous Close$0.8173Today's Range$0.7201 - $0.8452-Week Range$0.72 - $24.60Volume353,806 shsAverage Volume146,999 shsMarket Capitalization$1.86 millionP/E Ratio-0.03Dividend YieldN/ABeta1.72 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California. Receive BIOC News and Ratings via Email Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOC Previous Symbol CUSIPN/A Webwww.biocept.com Phone858-320-8200 Debt Debt-to-Equity Ratio0.11 Current Ratio2.63 Quick Ratio2.50 Price-To-Earnings Trailing P/E Ratio-0.03 Forward P/E Ratio-0.09 P/E GrowthN/A Sales & Book Value Annual Sales$5.07 million Price / Sales0.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book1.34 Profitability EPS (Most Recent Fiscal Year)($23.72) Net Income$-21,610,000.00 Net Margins-715.42% Return on Equity-456.20% Return on Assets-215.56% Miscellaneous Employees95 Outstanding Shares2,270,000Market Cap$1.86 million OptionableOptionable Biocept (NASDAQ:BIOC) Frequently Asked Questions What is Biocept's stock symbol? Biocept trades on the NASDAQ under the ticker symbol "BIOC." How were Biocept's earnings last quarter? Biocept Inc (NASDAQ:BIOC) issued its quarterly earnings results on Tuesday, November, 13th. The medical research company reported ($2.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.71) by $0.71. The medical research company earned $0.76 million during the quarter, compared to analyst estimates of $1.02 million. Biocept had a negative net margin of 715.42% and a negative return on equity of 456.20%. View Biocept's Earnings History. When is Biocept's next earnings date? Biocept is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Biocept. What price target have analysts set for BIOC? 2 equities research analysts have issued twelve-month target prices for Biocept's stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Biocept's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 22.4% from the stock's current price. View Analyst Price Targets for Biocept. What is the consensus analysts' recommendation for Biocept? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept. Has Biocept been receiving favorable news coverage? Media headlines about BIOC stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biocept earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. Who are some of Biocept's key competitors? Some companies that are related to Biocept include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Guardant Health (GH), Genomic Health (GHDX), CareDx (CDNA), Natera (NTRA), InVitae (NVTA), RadNet (RDNT), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD) and PotNetwork (POTN). Who are Biocept's key executives? Biocept's management team includes the folowing people: Mr. Michael W. Nall, CEO, Pres & Director (Age 55)Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Sec. (Age 60)Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer & Member of Scientific Advisory Board (Age 71)Dr. Soon Kap Hahn Ph.D., FounderMr. Pavel Tsinberg, Director of Technology Devel. Who are Biocept's major shareholders? Biocept's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (1.74%) and Vanguard Group Inc (0.88%). View Institutional Ownership Trends for Biocept. Which institutional investors are selling Biocept stock? BIOC stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. View Insider Buying and Selling for Biocept. Which institutional investors are buying Biocept stock? BIOC stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP. View Insider Buying and Selling for Biocept. How do I buy shares of Biocept? Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Biocept's stock price today? One share of BIOC stock can currently be purchased for approximately $0.8173. How big of a company is Biocept? Biocept has a market capitalization of $1.86 million and generates $5.07 million in revenue each year. The medical research company earns $-21,610,000.00 in net income (profit) each year or ($23.72) on an earnings per share basis. Biocept employs 95 workers across the globe. What is Biocept's official website? The official website for Biocept is http://www.biocept.com. How can I contact Biocept? Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected] MarketBeat Community Rating for Biocept (NASDAQ BIOC)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 218 (Vote Outperform)Underperform Votes: 244 (Vote Underperform)Total Votes: 462MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: Why is insider trading harmful?